GSK completes Nuvalent acquisition, adds three NSCLC assets
- Aggregate equity value approximately $10.6 billion; net of cash acquired, GSK’s investment ≈ $9.4 billion.
- Adds three non‑small cell lung cancer (NSCLC) candidates: zidesamtinib (NVL‑520), neladalkib (NVL‑655) and NVL‑330.
- Zidesamtinib and neladalkib are under FDA review for ROS1‑positive and ALK‑altered NSCLC, have Breakthrough Therapy and Orphan Drug designations, with target decision dates later this year.
- If approved, zidesamtinib and neladalkib are expected to launch in 2026 and are described as having multi‑blockbuster potential.
Deal completion
GSK has completed its acquisition of Nuvalent, a Boston‑based clinical‑stage company focused on precisely targeted oncology therapies.
Assets acquired
The purchase adds three lung cancer candidates to GSK’s portfolio: zidesamtinib (NVL‑520) and neladalkib (NVL‑655), both positioned as potential best‑in‑class agents, and NVL‑330, currently in phase I for HER2‑altered NSCLC.
Regulatory status and timelines
Zidesamtinib and neladalkib are under FDA review for ROS1‑positive and ALK‑altered non‑small cell lung cancer, have received Breakthrough Therapy and Orphan Drug designations, and carry target decision dates later this year; expected launches, if approved, are in 2026.
Financial terms and strategic context
The aggregate equity value of the transaction is approximately $10.6 billion (£8.0 billion); net of cash acquired GSK’s aggregate investment is about $9.4 billion (£7.1 billion). GSK says the deal accelerates its entry into lung cancer and complements its broader oncology priorities, including antibody‑drug conjugate programmes and selective kinase inhibitors.
Source: GSK
